Shalby climbs as its arm gets nod to market, sell Knee Implants, Hip Systems, Knee, Hip Instruments
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Shalby is currently trading at Rs. 138.50, up by 2.45 points or 1.80% from its previous closing of Rs. 136.05 on the BSE.
The scrip opened at Rs. 139.00 and has touched a high and low of Rs. 142.75 and Rs. 138.25 respectively. So far 6185 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 167.95 on 09-Jan-2023 and a 52 week low of Rs. 95.10 on 23-Jun-2022.
Last one week high and low of the scrip stood at Rs. 145.95 and Rs. 135.15 respectively. The current market cap of the company is Rs. 1501.34 crore.
The promoters holding in the company stood at 74.12%, while Institutions and Non-Institutions held 4.03% and 21.85% respectively.
Shalby’s step?down subsidiary -- Shalby Global Technologies, Singapore (SGT) has received a regulatory approval to market and sell Knee Implants, Hip Systems, Knee and Hip Instruments, etc. by Ministry of Health, Indonesia. Now, SGT can import the said implants and medical devices from USA and sell in Indonesia.
This development is fully in line with company’s stated strategy to grow company’s Orthopaedic implant business and establish footprint in the Medical device market internationally. This is a big milestone achieved by the Shalby group in its journey to serve many more international patients. The synergies between the businesses are compelling and will bring in immediate benefits of sourcing US FDA approved quality implants into Indonesia through company’s distribution channels. Shalby has performed more than 1,44,000 joint replacement surgeries so far and continues to be the leader in India and globally in terms of the volume of surgeries performed annually.
Shalby is a chain of Multi-specialty tertiary care hospitals based out of Ahmedabad. It has combined bed strength of more than 700 beds with its multispecialty hospitals across Gujarat and Goa.
